Company / Net Debt per Share
ADMA Biologics, Inc. Net Debt per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Debt per Share
-$0.07
FY2025
5-year range
-$0.14 / -$0.07
FY2021-FY2025
Trend
+52.0%
vs FY2024
Sector context
#52 of 82
Health Care
What the data says
At $-0.07, ADMA Biologics, Inc.'s net debt per share ranks #31 of 82 in the Health Care sector. Net Debt per Share has increased for 4 consecutive years, from $-3.13 in FY2017 to $-0.07 in FY2025.
Based on SEC 10-K filings.
-0.07 in FY2025.
Increased from $-0.58 to $-0.07 over the past 6 years.
Health Care sector context is included.
Net Debt per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#31 of 82 in Health CareTop 37% of 82This company -$0.07 Sector average $1.13
▼
-105.8% below sector average
Key checks
Key Insights
- In FY2025, net debt per share increased 52.0% year-over-year.
- Ranks #52 out of 82 companies in the Health Care sector.
- Lowest net debt per share in the period was in FY2017.
Company context
Key Data Points
- Altman Z-Score 3.37 (safe zone, above 2.9 threshold)
- Strong profit margin: 46.4%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net Debt per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$0.07 | +52.0% |
| FY2024 | -$0.14 | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | -$0.58 | +11.7% |
| FY2018 | -$0.65 | +79.1% |
| FY2017 | -$3.13 | -312.8% |
| FY2016 | -$0.76 | - |
As of FY2025 · SEC 10-K · Updated Jul 1, 2026